Evolocumab

Therapeutic indications

Evolocumab is indicated for:

Primary hypercholesterolaemia (heterozygous familial and non-familial), mixed dyslipidaemia

Population group: only adults (18 years old or older)

Evolocumab is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Homozygous familial hypercholesterolaemia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Evolocumab is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Established atherosclerotic cardiovascular disease

Population group: only adults (18 years old or older)

Evolocumab is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

  • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: REPATHA Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈